Key Highlights: Implications: By preparing manufacturing and technology transfer now, Dr. Reddy’s can help expand long‑acting PrEP options beyond daily pills and six‑monthly injections, potentially improving adherence and access in resource‑limited settings while strengthening its HIV portfolio as Gilead advances the Phase 3 PURPOSE 365 trial. Source: ET Pharma...
Relevant Market Insights India’s biopharmaceutical sector is at a pivotal point in its evolution. Long celebrated as the world’s “pharmacy of the world” for generics and vaccines, the broader biopharma market is now defined by robust growth, expanding innovation, and compelling projections for the coming decade. Supported by strong domestic demand, favourable government policy, and...
Latest Developments in Specialty Pharma India’s pharmaceutical industry has built a global reputation as a leading supplier of affordable generic medicines. Over the past two decades, Indian companies have established strong capabilities in large-scale manufacturing, regulatory compliance, and cost-efficient drug production. However, as global competition intensifies and pricing pressures increase in traditional generics markets, many...
Summary India’s pharmaceutical industry is beginning to move from a manufacturing-led model toward a more technology-driven approach to drug discovery, with AI emerging as an important part of that transition. India has already produced more than 10 novel drug assets over the past decade, while PE/VC investment in pharma increased 2.1-fold to $731 million in...
Summary The Top 10 R&D Spending Indian Biopharma Companies of 2026 reflect the country’s growing commitment to pharmaceutical innovation, advanced drug development, and long-term global competitiveness. Led by Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Zydus Lifesciences, these companies collectively invested billions of rupees in research and development during FY2025-26 to strengthen pipelines across specialty medicines, biosimilars, biologics, vaccines, complex...
Key Highlights: Implications: Gland Pharma’s move to acquire Gland Pharma USA Inc. directly from its Singapore intermediate holding company is a purely internal restructuring that removes one corporate layer between the Indian parent and its US marketing and distribution arm. The transaction, valued at about USD 0.5 million on an arm’s‑length basis, is not expected...
Key Highlights: Implications: Dr. Reddy’s has secured CDSCO approval for its abatacept biosimilar (250 mg IV) for adults with moderate‑to‑severe active rheumatoid arthritis and active psoriatic arthritis who failed other DMARDs, with manufacturing at its Bachupally biologics facility and supply support from Gland Pharma. The approval is conditional on a Phase IV study (protocol due within 3...
